

UNITED STATES PATENT AND TRADEMARK OFFICE
Trademark Trial and Appeal Board
P.O. Box 1451
Alexandria, VA 22313-1451
General Contact Number: 571-272-8500

BUO/nmt

Mailed: May 8, 2015

Opposition No. 91220279

Santhera Pharmaceuticals Holding AG

v.

Majid M. Seraj, Pharm.D.

By the Trademark Trial and Appeal Board:

On April 27, 2015, the parties filed a stipulated proposed amendment to application Serial No. 86269204, and withdrawal of the opposition without prejudice, contingent upon entry of the amendment.¹

By the proposed amendment the parties seek to amend the identification of goods in International Class 5 as follows:

from

Pharmaceutical preparations acting on the central nervous system;
Pharmaceutical preparations for use in chemotherapy;
Pharmaceutical preparations, namely, an analgesic for human
consumption taken orally; Pharmaceutical products for
ophthalmological use; Pharmaceuticals, namely, psychotropics.

to

¹ The motion also indicated that the parties would like to relinquish any remaining extensions of time to oppose that are currently pending. The parties are advised that they must file a request to that effect in each one of the currently pending cases they desire to relinquish the extension of time to oppose.

Pharmaceutical preparations and substances for the treatment and prevention of mood disorders, psychosis, anxiety, epilepsy, pain management and nausea.

Inasmuch as the amendment is clearly limiting in nature as required by Trademark Rule 2.71(a), and because Opposer consents, the amendment is **APPROVED** and **ENTERED**. See Trademark Rule 2.133(a).

The contingency in Opposer's withdrawal having been met, the opposition is **DISMISSED** without prejudice.